STOCK TITAN

Vanguard reports 130.7M shares in Abbott Laboratories (ABT) — 7.5% stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Abbott Laboratories shareholder disclosure: Vanguard Capital Management reports beneficial ownership of 130,676,776 shares of Abbott Laboratories common stock, representing 7.5% of the class as of the filing. The filing shows sole dispositive power over 130,676,776 shares and sole voting power for 17,726,843 shares. The form is signed on 04/29/2026.

Positive

  • None.

Negative

  • None.

Insights

Large passive holding disclosed by Vanguard Capital Management.

Vanguard Capital Management reports beneficial ownership of 130,676,776 shares (7.5%) of Abbott Laboratories common stock. The filing attributes sole dispositive authority for the full share amount and sole voting authority for 17,726,843 shares, consistent with an asset-manager aggregation.

Ownership is reported on behalf of funds and managed accounts; cash‑flow recipients and other affiliates are described in the statement. Subsequent Schedule 13 filings could adjust these counts if holdings change.

Shares beneficially owned 130,676,776 shares Amount reported beneficially owned
Percent of class 7.5 % Percent of common stock class reported
Sole voting power 17,726,843 shares Shares with sole power to vote
Sole dispositive power 130,676,776 shares Shares with sole power to dispose
Filing signature date 04/29/2026 Date signed by reporting person
Schedule 13G regulatory
"Vanguard Capital Management 2 | ... SCHEDULE 13G"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Beneficial ownership financial
"Amount beneficially owned: 130676776"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Sole dispositive power regulatory
"Sole power to dispose or to direct the disposition of: 130676776"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Sole voting power regulatory
"Sole power to vote or to direct the vote: 17726843"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.





002824100

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.


SCHEDULE 13G



Vanguard Capital Management
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:04/29/2026

FAQ

What stake does Vanguard hold in Abbott Laboratories (ABT)?

Vanguard Capital Management reports beneficial ownership of 130,676,776 shares, equal to 7.5% of Abbott Laboratories common stock as stated in the filing.

How much voting power does Vanguard report for ABT?

The filing shows Vanguard has sole voting power over 17,726,843 shares and reports no shared voting power for the disclosed position.

Who controls dividend or sale proceeds for the reported ABT shares?

Vanguard states it has the right to receive or direct dividends or sale proceeds for the reported holdings, including shares held by Vanguard funds and managed accounts.

When was the Schedule 13G for ABT signed by Vanguard?

The filing is signed by Ashley Grim, Head of Global Fund Administration, on 04/29/2026, per the signature block in the submission.